Safety and Tolerability of Tegaserod in Irritable Bowel Syndrome Management
- 1 January 2004
- journal article
- review article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 44 (1) , 41-51
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- An open label study to determine the efficacy and tolerability of tegaserod in the treatment of constipation dominant irritable bowel syndrome (IBS-C)Gastroenterology, 2003
- Tegaserod is an effective and safe therapy for irritable bowel syndrome in a nordic populationGastroenterology, 2003
- Irritable Bowel SyndromeJournal of Clinical Gastroenterology, 2002
- The complexity of drug development for irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2002
- TegaserodJournal of Clinical Gastroenterology, 2002
- Serotoninergic neuroenteric modulatorsThe Lancet, 2001
- The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy SubjectsThe Journal of Clinical Pharmacology, 2001
- Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjectsGastroenterology, 2000
- Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsGastroenterology, 2000
- Irritable bowel-type symptoms in HMO examineesDigestive Diseases and Sciences, 1993